Red Tape, Paperasserie, Papierkrieg, Papeleo ...

The clock is ticking for the implementation of a common set of rules that will regulate the conduct of clinical trials in EU member states. The European Commission (EC) passed the EU directive on clinical trials in May 2001 in an attempt to simplify the clinical testing of medicines in Europe and to ensure that trials meet the highest standards of quality. Member states must comply with the new rules by May 1, 2004. But, some scientists worry that the proposed regulations will damage noncommer

Written byMartina Habeck
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

The clock is ticking for the implementation of a common set of rules that will regulate the conduct of clinical trials in EU member states. The European Commission (EC) passed the EU directive on clinical trials in May 2001 in an attempt to simplify the clinical testing of medicines in Europe and to ensure that trials meet the highest standards of quality. Member states must comply with the new rules by May 1, 2004. But, some scientists worry that the proposed regulations will damage noncommercial clinical research.

The rules were originally designed with licensing trials in mind. The EC extended them to cover not only commercially funded trials, but also those sponsored by government, charities, or academic institutions. As a result, even the most basic clinical trials will be required to comply with standards of good clinical practice, and in most cases, this means extra paperwork, inspections, and extensive data ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies